HHS issues contracts for pandemic vaccine research
GlaxoSmithKline has won a $63.3 million contract from Health and Human Services to develop pre-pandemic and pandemic vaccines, supporting its research into adjuvants that boost the effectiveness of vaccines. The 5-year contract also gives the U.S. Government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines. Iomai, meanwhile, announced it will receive a contract from HHS to fund the development of a dose-sparing patch for use with a pandemic influenza vaccine.
A limited global supply capacity of flu antigen makes it critical that we use innovative adjuvant system technology to produce a new generation of flu pandemic vaccines," said David Stout, president of pharmaceuticals at GlaxoSmithKline.
- here's the release on GSK's contract
- and here's the release on Iomai
Related Articles:
HHS awards H5N1 contracts. Report
Switzerland to stockpile GSK's bird flu vaccine. Report
Novartis wins $220M flu vaccine contract. Report
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets


